MX389207B - Composiciones de nicotinamida ribósido y pteroestilbeno y métodos para el tratamiento de trastornos de la piel. - Google Patents
Composiciones de nicotinamida ribósido y pteroestilbeno y métodos para el tratamiento de trastornos de la piel.Info
- Publication number
- MX389207B MX389207B MX2017016024A MX2017016024A MX389207B MX 389207 B MX389207 B MX 389207B MX 2017016024 A MX2017016024 A MX 2017016024A MX 2017016024 A MX2017016024 A MX 2017016024A MX 389207 B MX389207 B MX 389207B
- Authority
- MX
- Mexico
- Prior art keywords
- skin disorders
- compositions
- pterostilbene
- methods
- nicotinamide riboside
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 6
- JLEBZPBDRKPWTD-TURQNECASA-O N-ribosylnicotinamide Chemical group NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=C1 JLEBZPBDRKPWTD-TURQNECASA-O 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 235000020956 nicotinamide riboside Nutrition 0.000 title abstract 3
- 239000011618 nicotinamide riboside Substances 0.000 title abstract 3
- VLEUZFDZJKSGMX-ONEGZZNKSA-N pterostilbene Chemical compound COC1=CC(OC)=CC(\C=C\C=2C=CC(O)=CC=2)=C1 VLEUZFDZJKSGMX-ONEGZZNKSA-N 0.000 title abstract 3
- VLEUZFDZJKSGMX-UHFFFAOYSA-N pterostilbene Natural products COC1=CC(OC)=CC(C=CC=2C=CC(O)=CC=2)=C1 VLEUZFDZJKSGMX-UHFFFAOYSA-N 0.000 title abstract 3
- 208000017520 skin disease Diseases 0.000 abstract 7
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000000453 Skin Neoplasms Diseases 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 201000000849 skin cancer Diseases 0.000 abstract 1
- 230000036561 sun exposure Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
- A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
- A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/004—Aftersun preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562173733P | 2015-06-10 | 2015-06-10 | |
| PCT/US2016/019653 WO2016200447A1 (en) | 2015-06-10 | 2016-02-25 | Nicotinamide riboside and pterostilbene compositions and methods for treatment of skin disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017016024A MX2017016024A (es) | 2018-08-15 |
| MX389207B true MX389207B (es) | 2025-03-20 |
Family
ID=57503873
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017016024A MX389207B (es) | 2015-06-10 | 2016-02-25 | Composiciones de nicotinamida ribósido y pteroestilbeno y métodos para el tratamiento de trastornos de la piel. |
| MX2021012600A MX2021012600A (es) | 2015-06-10 | 2017-12-08 | Composiciones de nicotinamida ribosido y pteroestilbeno y metodos para el tratamiento de trastornos de la piel. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021012600A MX2021012600A (es) | 2015-06-10 | 2017-12-08 | Composiciones de nicotinamida ribosido y pteroestilbeno y metodos para el tratamiento de trastornos de la piel. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11426398B2 (enExample) |
| EP (1) | EP3307754B1 (enExample) |
| JP (1) | JP2018517774A (enExample) |
| KR (1) | KR20180021784A (enExample) |
| CN (1) | CN107849083A (enExample) |
| AU (2) | AU2016274126A1 (enExample) |
| CA (1) | CA2989115C (enExample) |
| ES (1) | ES2932801T3 (enExample) |
| MX (2) | MX389207B (enExample) |
| RU (1) | RU2017145692A (enExample) |
| TW (1) | TWI725033B (enExample) |
| WO (1) | WO2016200447A1 (enExample) |
| ZA (1) | ZA201800056B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016200447A1 (en) | 2015-06-10 | 2016-12-15 | Elysium Health, Inc. | Nicotinamide riboside and pterostilbene compositions and methods for treatment of skin disorders |
| JP6827113B2 (ja) | 2017-01-21 | 2021-02-10 | 広州白雲山漢方現代薬業有限公司Ｇｕａｎｇｚｈｏｕ Ｈａｎｆａｎｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．，Ｌｔｄ． | シェーグレン症候群の治療におけるペオニフロリン−６’−ｏ−ベンゼンスルホン酸の使用 |
| US11389468B2 (en) | 2017-03-17 | 2022-07-19 | Elysium Health, Inc. | Nicotinamide riboside for use in treating or preventing liver damage |
| US11129843B2 (en) * | 2017-04-24 | 2021-09-28 | Elysium Health, Inc. | Treating and preventing kidney damage |
| ES3004332T3 (en) * | 2017-05-17 | 2025-03-12 | Univ De Valencia Estudi General | Treating and preventing amyotrophic lateral sclerosis with nicotinamide riboside and pterostilbene |
| US20200085849A1 (en) * | 2017-05-18 | 2020-03-19 | Elysium Health, Inc. | Methods and compositions for improving sleep |
| WO2019023471A1 (en) * | 2017-07-28 | 2019-01-31 | Centers For Age Control, Inc. | COMPOSITIONS AND METHODS FOR PREVENTING AND INVERTING THE ASPECTS OF AGING |
| CN109589309A (zh) * | 2017-09-30 | 2019-04-09 | 浙江嘉华化工有限公司 | 烟酰胺核糖微囊的制备方法 |
| US20200330497A1 (en) * | 2017-10-19 | 2020-10-22 | Elysium Health, Inc. | Prevention and treatment of tdp-43 associated diseases |
| WO2019108875A1 (en) * | 2017-12-01 | 2019-06-06 | Elysium Health, Inc. | Methods and compositions for treating glaucoma |
| WO2019108873A1 (en) * | 2017-12-01 | 2019-06-06 | Elysium Health, Inc. | Methods and compositions for treating multiple sclerosis |
| GB201811312D0 (en) * | 2018-07-10 | 2018-08-29 | Nuchido Ltd | Compositions |
| CN112955139B (zh) | 2018-09-25 | 2025-04-18 | 庞塞迪利昂健康特定活动公司 | 用于制备α-酮戊二酸钙的方法 |
| CN111569084B (zh) * | 2019-02-19 | 2021-07-13 | 中国科学院上海药物研究所 | 基于柳胺酚和紫檀芪的成环偶联分子dcz0801类化合物、其制备方法及用途 |
| EP3930728A1 (en) * | 2019-02-26 | 2022-01-05 | Universitat de Valencia - Estudi General | Methods and compositions for treating motor neuron diseases |
| WO2020190703A1 (en) * | 2019-03-21 | 2020-09-24 | Elysium Health, Inc. | Methods for wound treatment |
| CN113768946A (zh) * | 2020-05-25 | 2021-12-10 | 南京帝昌医药科技有限公司 | 一种治疗糖尿病皮肤并发症的软膏及其制备方法 |
| CN113712193A (zh) * | 2020-05-25 | 2021-11-30 | 南京帝昌医药科技有限公司 | 修复皮肤系统的组合物制备方法及其用途 |
| US20230270770A1 (en) * | 2020-07-30 | 2023-08-31 | Moises HERNANDEZ-VAZQUEZ | Nutritional supplements for repairing muscle and defending against deterioration from human aging |
| CA3227520A1 (en) * | 2021-08-02 | 2023-02-09 | Laurent GARCON | Nicotinamide mononucleotide derivatives for use in the treatment of sapho syndrome |
| WO2023119230A1 (en) | 2021-12-22 | 2023-06-29 | L'oreal | Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| DK1957086T3 (en) * | 2005-11-18 | 2018-06-06 | Cornell Res Foundation Inc | NICOTINOYL RIBOSIDE COMPOSITIONS AND METHODS OF USE |
| EP2322159A1 (en) | 2009-10-30 | 2011-05-18 | Green Molecular, S.L. | Use of pterostilbene (pter) as medicament for prevention and/or treatment of skin diseases, damages or injures or as cosmetic |
| CN103547256A (zh) | 2011-03-23 | 2014-01-29 | 加利福尼亚大学校务委员会 | 炎性和传染性皮肤病的治疗 |
| US8841350B2 (en) * | 2011-05-11 | 2014-09-23 | ChromaDex Inc. | Method for inducing UDP-glucuronosyltransferase activity using pterostilbene |
| US20130296440A1 (en) | 2012-05-01 | 2013-11-07 | ChromaDex Inc. | Pterostilbene and curcumin combination for treatment of oxidative stress and inflammation |
| CN105873937A (zh) | 2013-10-30 | 2016-08-17 | 可劳迈戴斯有限公司 | 用于在治疗皮肤病中局部使用的烟酰胺核苷组合物 |
| BR112016028672A2 (pt) * | 2014-06-06 | 2017-08-22 | Glaxosmithkline Ip No 2 Ltd | análogos de ribosídeo de nicotinamida e composições farmacêuticas e usos do mesmo |
| MX390185B (es) * | 2015-03-16 | 2025-03-20 | Chromadex Inc | Composiciones de acido nicotinico ribosido o de nicotinamida ribosido, derivados reducidos de los mismos, y su uso. |
| WO2016149277A1 (en) * | 2015-03-17 | 2016-09-22 | Specialty Nutrition Group, Inc. | Nutritional compositions to enhance mitochondrial energy production |
| WO2016200447A1 (en) | 2015-06-10 | 2016-12-15 | Elysium Health, Inc. | Nicotinamide riboside and pterostilbene compositions and methods for treatment of skin disorders |
-
2016
- 2016-02-25 WO PCT/US2016/019653 patent/WO2016200447A1/en not_active Ceased
- 2016-02-25 CN CN201680046668.7A patent/CN107849083A/zh active Pending
- 2016-02-25 MX MX2017016024A patent/MX389207B/es unknown
- 2016-02-25 ES ES16807940T patent/ES2932801T3/es active Active
- 2016-02-25 CA CA2989115A patent/CA2989115C/en active Active
- 2016-02-25 EP EP16807940.8A patent/EP3307754B1/en active Active
- 2016-02-25 US US15/735,066 patent/US11426398B2/en active Active
- 2016-02-25 RU RU2017145692A patent/RU2017145692A/ru unknown
- 2016-02-25 KR KR1020187000353A patent/KR20180021784A/ko not_active Ceased
- 2016-02-25 AU AU2016274126A patent/AU2016274126A1/en not_active Abandoned
- 2016-02-25 JP JP2018517123A patent/JP2018517774A/ja active Pending
- 2016-06-13 TW TW105118370A patent/TWI725033B/zh active
-
2017
- 2017-12-08 MX MX2021012600A patent/MX2021012600A/es unknown
-
2018
- 2018-01-04 ZA ZA2018/00056A patent/ZA201800056B/en unknown
-
2020
- 2020-12-08 AU AU2020286208A patent/AU2020286208B2/en active Active
-
2022
- 2022-07-25 US US17/872,575 patent/US12109206B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| TWI725033B (zh) | 2021-04-21 |
| US12109206B2 (en) | 2024-10-08 |
| WO2016200447A1 (en) | 2016-12-15 |
| EP3307754B1 (en) | 2022-09-14 |
| CN107849083A (zh) | 2018-03-27 |
| MX2017016024A (es) | 2018-08-15 |
| EP3307754A1 (en) | 2018-04-18 |
| JP2018517774A (ja) | 2018-07-05 |
| CA2989115C (en) | 2024-01-02 |
| US20180353497A1 (en) | 2018-12-13 |
| AU2020286208B2 (en) | 2022-11-10 |
| AU2020286208A1 (en) | 2021-01-07 |
| RU2017145692A (ru) | 2019-07-10 |
| AU2016274126A1 (en) | 2018-01-18 |
| ZA201800056B (en) | 2023-10-25 |
| KR20180021784A (ko) | 2018-03-05 |
| EP3307754A4 (en) | 2019-03-27 |
| CA2989115A1 (en) | 2016-12-15 |
| US11426398B2 (en) | 2022-08-30 |
| MX2021012600A (es) | 2021-11-12 |
| ES2932801T3 (es) | 2023-01-26 |
| RU2017145692A3 (enExample) | 2019-07-31 |
| TW201713322A (zh) | 2017-04-16 |
| US20220362233A1 (en) | 2022-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX389207B (es) | Composiciones de nicotinamida ribósido y pteroestilbeno y métodos para el tratamiento de trastornos de la piel. | |
| CY1122344T1 (el) | Blautia stercosis και wexlerae για χρηση στην θεραπευτικη αγωγη φλεγμονωδων και αυτοανοσων νοσων | |
| CL2018002814A1 (es) | Composiciones y metodos para el tratamiento de heridas, trastornos, y enfermedades de la piel. | |
| PH12018500586B1 (en) | Farnesoid x receptor agonists and uses thereof | |
| MX388693B (es) | Composiciones de nanoparticulas para terapia sostenida. | |
| CL2019000935A1 (es) | Composición farmacéutica, métodos para tratamiento y usos de la misma. | |
| MX2018005315A (es) | Composiciones y metodos para el tratamiento del cancer. | |
| CO2017005784A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
| MX2018004515A (es) | Agentes de anticuerpo especificos para cd19 humano y usos de los mismos. | |
| MX378273B (es) | Compuestos activos hacia bromodominios. | |
| MX384490B (es) | Agentes que inducen apoptosis para el tratamiento de cancer y enfermedades inmunitarias y autoinmunitarias. | |
| GB2541571A (en) | Pharmaceutical compositions | |
| MX377141B (es) | Composiciones y metodos para modular la expresion de pkk. | |
| MX374399B (es) | Composiciones y sus usos para tratar y prevenir la enfermedad de huntington. | |
| EP4252851A3 (en) | Ezh2 inhibitors for treating lymphoma | |
| CO2017007121A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
| SG10201808835QA (en) | Anti-siglec-8 antibodies and methods of use thereof | |
| CL2018001108A1 (es) | Composiciones y métodos para transducción de tumores | |
| WO2017079570A3 (en) | Splise-switching oligonucleotides and methods of use | |
| MX379271B (es) | Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cáncer. | |
| MX2020003762A (es) | Composiciones cosmeticas y metodo para tratar la piel. | |
| DK3383872T3 (da) | 1,3,4-thiadiazolforbindelser og anvendelse deraf i cancerbehandling | |
| MX382092B (es) | Compuestos heterocíclicos para el tratamiento de enfermedades. | |
| TW201713323A (en) | Therapeutic compositions and methods of use thereof | |
| TR201905392T4 (tr) | Ağrı tedavisi. |